Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BMRN
DateTimeSourceHeadlineSymbolCompany
06/11/202413:00PR Newswire (US)BioMarin to Participate in Three Upcoming Investor ConferencesNASDAQ:BMRNBioMarin Pharmaceutical Inc
31/10/202419:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BMRNBioMarin Pharmaceutical Inc
29/10/202420:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMRNBioMarin Pharmaceutical Inc
29/10/202420:03PR Newswire (US)BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and OutlookNASDAQ:BMRNBioMarin Pharmaceutical Inc
24/10/202411:00GlobeNewswire Inc.Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug CandidateNASDAQ:BMRNBioMarin Pharmaceutical Inc
16/10/202412:30PR Newswire (US)BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ETNASDAQ:BMRNBioMarin Pharmaceutical Inc
01/10/202420:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
01/10/202420:50Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
30/09/202420:29Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:BMRNBioMarin Pharmaceutical Inc
24/09/202412:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMRNBioMarin Pharmaceutical Inc
18/09/202412:00PR Newswire (US)BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society MeetingNASDAQ:BMRNBioMarin Pharmaceutical Inc
17/09/202421:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
04/09/202417:00PR Newswire (US)BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial GuidanceNASDAQ:BMRNBioMarin Pharmaceutical Inc
04/09/202416:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMRNBioMarin Pharmaceutical Inc
04/09/202411:30PR Newswire (US)BioMarin to Host Investor Day Today at 10:30 a.m. Eastern TimeNASDAQ:BMRNBioMarin Pharmaceutical Inc
29/08/202412:00PR Newswire (US)BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NYNASDAQ:BMRNBioMarin Pharmaceutical Inc
28/08/202421:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMRNBioMarin Pharmaceutical Inc
22/08/202421:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMRNBioMarin Pharmaceutical Inc
21/08/202412:30PR Newswire (US)BioMarin Announces New R&D and Business Development LeadershipNASDAQ:BMRNBioMarin Pharmaceutical Inc
19/08/202413:00PR Newswire (US)BioMarin to Host 2024 Investor Day on September 4th in New YorkNASDAQ:BMRNBioMarin Pharmaceutical Inc
15/08/202419:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
13/08/202415:48Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
05/08/202420:35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BMRNBioMarin Pharmaceutical Inc
05/08/202420:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMRNBioMarin Pharmaceutical Inc
05/08/202420:03PR Newswire (US)BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 GuidanceNASDAQ:BMRNBioMarin Pharmaceutical Inc
05/08/202420:01PR Newswire (US)BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and ItalyNASDAQ:BMRNBioMarin Pharmaceutical Inc
24/07/202420:05PR Newswire (US)U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 DiseaseNASDAQ:BMRNBioMarin Pharmaceutical Inc
23/07/202412:00PR Newswire (US)BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ETNASDAQ:BMRNBioMarin Pharmaceutical Inc
17/06/202412:30PR Newswire (US)BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone HealthNASDAQ:BMRNBioMarin Pharmaceutical Inc
07/06/202422:09PR Newswire (US)KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600NASDAQ:BMRNBioMarin Pharmaceutical Inc
 Showing the most relevant articles for your search:NASDAQ:BMRN